

Invitation

3rd Northern European
Multidisciplinary RCC Meeting (NEMDRCC)

Copenhagen June 15th and 16th 2018



Pfizer b.v.
Postbus 37
2900 AA Capelle a/d IJssel
www.pfizer.nl

PP-SUT-NLD-0107

I am interested to join the Northern European
Multidisciplinary RCC meeting in Copenhagen
15th and 16th of June 2018



3rd Northern European Multidisciplinary RCC Meeting (NEMDRCC)

Copenhagen June 15th and 16th 2018

It is with great pleasure we are able to invite to the 3rd Northern European Multidisciplinary RCC meeting at Phoenix Hotel in Copenhagen, June 15th and 16th 2018 (www.phoenixcopenhagen.dk). The hotel is located in the center of Copenhagen and is easily accessible from the airport and metro.

The focus of the RCC meetings is to bring together oncologists, urologists, pathologists, radiologists, and scientists involved in clinical and research aspects of renal cell carcinoma. Therefore, the 3rd Northern European Multidisciplinary RCC meeting will provide a multidisciplinary forum for the exchange of ideas and information for research and treatment of RCC. During the meeting, adequate time is allocated for Q & A and discussions, enabling high participant involvement.

A special focus of the meeting is to stimulate interest in RCC from "next-generation" doctors and researchers. Therefore, the organizing committee encourages the attendance of younger doctors and researchers in the meeting. All attendees are encouraged to submit an abstract (e.g. current research or a real-life clinical case report), and the best abstracts will be selected for oral presentations.

Having both junior and senior doctors out of the hospital at the same time, the meeting must take place outside of normal working hours. We therefore welcome you to Copenhagen for a Friday-night-Saturday-morning meeting in the middle of Copenhagen for an informative and informal meeting.

Pfizer provides funding and infrastructure for the meeting but is not involved in the scientific program.

The program is made by an independent scientific planning committee:

Frede Donskov (DK) Chairman
Bjarne Kromann (DK)
Petri Bono (FI)
Ulrika Harmenberg (SE)
Christoph Müller (NO)
Börje Ljungberg (SE)
Benoit Beuselinck (BE)

If you have any questions or need further information, please contact Maurits Blesgraaf (Maurits.Blesgraaf@pfizer.com) or Nadja van de Kraats (Nadja.Vandekraats@pfizer.com)

Best regards on behalf of **the Planning Committee** and **Pfizer Oncology**

Program Friday June 15th

16.30 - 17.00 **Sandwich**
17.00 - 17.05 **Welcome remarks** *Frede Donskov, Denmark*

Chairman: Börje Ljungberg, Sweden

Impact of local control - current challenges:

17.05 - 17.30 **Impact of cytoreductive nephrectomy in synchronous metastatic RCC** *Christian Beisland, Norway*
17.30 - 17.55 **Open, laparoscopic or robotic-assisted partial nephrectomy for RCC. Does lymphadenectomy have a place?** *Nessn Azawi, Denmark*
17.55 - 18.15 **Cryoablation for small renal masses** *Tommy Kjærgaard Nielsen, Denmark*
18.15 - 18.35 **Q & A - discussion about surgery and cryoablation**

Clinical trial report:

18.35 - 18.50 **Spinal analgesia improves surgical outcome after open nephrectomy for renal cell carcinoma** *Börje Ljungberg, Sweden*

Update from DaRenCa - the Danish Renal Cancer Study Group:

18.50 - 19.00 **A new tool to register recurrent RCC, and curative intended treatments.** *Bjarne Kromann-Andersen, Denmark*

Oral abstract presentations:

19.00 - 19.10 **Oral abstract - presenter to be selected from submitted abstracts**
19.10 - 19.20 **Oral abstract - presenter to be selected from submitted abstracts**
19.20 - 19.30 **Oral abstract - presenter to be selected from submitted abstracts**
19.30 **Dinner & networking**

Program Saturday June 16th

7.00 **Breakfast**

Chairman: Benoit Beuselinck, Belgium

Keynote speaker:

8.00 - 8.45 **The combat of targeting Vascular Endothelial Growth Factor in Kidney Cancer** *Brian Rini, USA*
8.45 - 8.50 **Q & A - discussion**

From bench to clinic - and from clinic to bench:

8.50 - 9.10 **Genetic polymorphisms and sunitinib pharmacokinetics and pharmacodynamics** *Benoit Beuselinck, Belgium*
9.10 - 9.15 **Q & A - discussion**
9.15 - 9.25 **Oral abstract - presenter to be selected from submitted abstracts**
9.25 - 9.55 **Coffee break**
9.55 - 10.15 **Update on select adjuvant clinical trials: What to do?** *Frede Donskov, Denmark*
10.15 - 10.25 **Discussion**
10.25 - 10.40 **Prognostic role of neutrophil-lymphocyte ratio in RCC** *Maria Møller Pedersen, Denmark*

Survival update in the nordic countries:

10.40 - 10.50 **Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study** *Jan Oldenburg, Norway*
10.50 - 11.00 **Overall survival in renal cell carcinoma after introduction of targeted therapies: a Swedish population-based study** *Magnus Lindskog, Sweden*
11.00 - 11.05 **Discussion**
11.05 - 11.30 **Coffee break**

Current clinical challenges in mRCC:

11.30 - 12.05 **Check-point inhibitors in RCC. Efficacy, toxicity and subsequent therapy** *Laurence Albiges, France*
12.05 - 12.15 **Q & A - discussion**
12.15 - 12.30 **The predictive value of expression profiling in metastatic ccRCC undergoing metastasectomy** *Annelies Verbiest, Belgium*

Oral abstract presentations:

12.30 - 12.40 **Oral abstract - presenter to be selected from submitted abstracts**
12.40 - 12.50 **Oral abstract - presenter to be selected from submitted abstracts**
12.50 - 13.00 **Oral abstract - presenter to be selected from submitted abstracts**
13.00 **Closing remarks Frede Donskov, Denmark**
13.05 - 14.00 **Lunch & networking**

I am interested to join
the Northern European
Multidisciplinary RCC
meeting in Copenhagen
15th and 16th of June 2018

Yes



Name _____
Hospital _____
Address _____
E-mail _____